生命科学资讯

NIH imposes full ban of aborted fetal tissue in research

BMS pens $850M solid tumor pact with T-cell engager biotech Janux

Corcept racks up phase 3 cancer win to bounce back from FDA Cushing's rejection

Corxel secures $287M series D to fund phase 2/3 obesity studies of oral GLP-1 drug

Hoth strikes back against cancer drug skin toxicities, but share price stays frozen

Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ

FDA outlines draft policy on MRD, complete response for accelerated approvals in multiple myeloma

IO mulls more layoffs months after halving head count in wake of cancer vaccine setback

Touching base: Beam CEO on gene editing biotech's 'big push' for in vivo delivery

Cancer imaging company buys Lisata for phase 2-stage solid tumor drug

Novo Nordisk offloads diabetes assets to Aspect amid cell therapy retreat

Worldwide Clinical Trials adds Catalyst Clinical to global CRO mixture

Nkarta’s CEO wore head-to-toe pink at JPM. Here’s why it matters more than ever

Former Spero execs fined by SEC over antibiotic efficacy claims

Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years

Boundless finally gives up on combo treatment of 2 unimpressive cancer drugs

Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis

Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark

Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs

GSK pays $2.2B to buy Rapt for its phase 2-stage food allergy challenger to Xolair